

Genedrive®

CYP2C19 ID Kit

Pharmacogenetic test to inform clinicians on an individual's CYP2C19 genotype and CPIC-coded metaboliser status

The **only** point-of-care genetic test to aid clinicians' therapeutic treatment decisions, for drugs that are metabolised by CYP2C19, and that are specifically affected by DNA variant alleles ***2, *3, *4, *8, *17 and *35**.



Key Features



Supports personalised treatment using antiplatelet therapies



Non-invasive test, using buccal swabs



Rapid actionable results in approximately 69 minutes including diplotype and CPIC-coded metaboliser status



No cold storage required for reagents



Comprehensive variant coverage identifying clinically relevant alleles of CYP2C19 Loss of Function (*2, *3, *4, *8, *35) and gain of function (*17)

The Clinical Need: Stroke

There are...

100,000

Strokes
each year in
the UK

38,000

UK annual
stroke deaths

£10.2B

Estimated
NHS cost of
stroke by 2035

5 minutes

How often a stroke
strikes in the UK



Stroke Treatment

Clopidogrel is an antiplatelet treatment for secondary prevention of minor strokes and transient ischaemic attack (TIA), also known as a mini stroke.

CYP2C19 intermediate and poor metabolisers who receive clopidogrel experience reduced platelet inhibition and increased risk for major adverse cardiovascular and cerebrovascular events.

£15M

NHS England
clopidogrel spend
2022-2023


NICE Recommendation

Use CYP2C19 genotyping to assess if clopidogrel is suitable for patients with ischaemic stroke or TIA.

The **Genedrive® CYP2C19 ID Kit** should be used as the point of care test of choice.



For more information,
contact us at
enquiries@genedrive.com



CE
2962

genedrive